This video delves into the complexities of clinical trials and treatment for dementia. Professor Dr. Matthew Kiernan discusses the limitations of current trial models, the need for personalized biomarkers, and the challenges of using a one-size-fits-all approach.
Related content
Social and physical exposome factors—like poverty, pollution, and inequality—accumulate over time, shaping biological aging and cognitive decline. Through inflammation and cellular stress, these exposures drive neurodegeneration, highlighting the need for longitudinal, integrative research.
The exposome reframes dementia as the product of cumulative physical and social exposures-like pollution, nutrition, and inequality-across life. These factors shape brain aging through inflammation and epigenetic change. Lifespan, global studies are key to equitable dementia prevention.
Protocol for a multi-arm, multi-stage platform trial, whereby patients are randomly assigned to one of four sub-studies and then further randomly assigned to receive active treatment or placebo. Such a protocol determines patient selection and outcome measures, incorporating biomarkers across the different sub-studies.